QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)
QQQ   438.07 (+2.93%)
AAPL   184.37 (+1.12%)
MSFT   411.65 (+2.35%)
META   486.13 (+3.87%)
GOOGL   144.09 (+1.08%)
AMZN   174.58 (+3.55%)
TSLA   197.41 (+1.36%)
NVDA   785.38 (+16.40%)
NIO   5.85 (-2.01%)
AMD   181.86 (+10.69%)
BABA   76.12 (+0.70%)
T   16.59 (-2.41%)
F   12.12 (-0.16%)
MU   85.91 (+5.42%)
CGC   3.37 (-2.03%)
GE   151.67 (+1.74%)
DIS   107.63 (-0.04%)
AMC   4.42 (-3.28%)
PFE   27.55 (-0.43%)
PYPL   58.35 (+1.51%)
XOM   104.76 (-0.09%)

Natera (NTRA) Stock Price, News & Analysis

$71.15
+1.39 (+1.99%)
(As of 02/22/2024 ET)
Today's Range
$69.74
$71.74
50-Day Range
$57.28
$70.97
52-Week Range
$36.90
$71.74
Volume
933,380 shs
Average Volume
1.38 million shs
Market Capitalization
$8.55 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.85

Natera MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
2.4% Upside
$72.85 Price Target
Short Interest
Bearish
6.53% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.08mentions of Natera in the last 14 days
Based on 19 Articles This Week
Insider Trading
Selling Shares
$51.34 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($3.88) to ($2.66) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.97 out of 5 stars

Medical Sector

805th out of 934 stocks

Medical Laboratories Industry

18th out of 21 stocks


NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company's products also comprise Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

Natera Stock (NASDAQ:NTRA), Short Interest Report
Raymond James Downgrades Natera (NTRA)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
A Glimpse Into The Expert Outlook On Natera Through 9 Analysts
Natera (NASDAQ:NTRA) Downgraded by Raymond James to "Outperform"
Raymond James gets more bearish on Natera, downgrades shares
New Trump Bombshell
I believe Donald J. Trump will go down as America’s last Republican president.  But NOT for the reasons you may think…  If I’m right, the soul of this country will change forever…
Natera (NASDAQ:NTRA) Raised to "Hold" at StockNews.com
NTRA Mar 2024 90.000 call
NTRA Apr 2024 90.000 call
Natera Inc Director Herm Rosenman Sells 93,901 Shares
New Study Validates Signatera™ in Endometrial Cancer
CareDx Issues Statement in Patent Infringement Case
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/08/2023
Today
2/22/2024
Next Earnings (Confirmed)
2/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,018
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$72.85
High Stock Price Target
$87.00
Low Stock Price Target
$48.00
Potential Upside/Downside
+2.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
12 Analysts

Profitability

Net Income
$-547,800,000.00
Pretax Margin
-50.45%

Debt

Sales & Book Value

Annual Sales
$820.22 million
Book Value
$7.23 per share

Miscellaneous

Free Float
108,834,000
Market Cap
$8.53 billion
Optionable
Optionable
Beta
1.34
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report














NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 11 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

12 Wall Street analysts have issued twelve-month target prices for Natera's stock. Their NTRA share price targets range from $48.00 to $87.00. On average, they expect the company's share price to reach $72.85 in the next year. This suggests a possible upside of 2.4% from the stock's current price.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 on January 1st, 2024. Since then, NTRA shares have increased by 13.6% and is now trading at $71.15.
View the best growth stocks for 2024 here
.

Are investors shorting Natera?

Natera saw a increase in short interest in January. As of January 31st, there was short interest totaling 7,840,000 shares, an increase of 13.6% from the January 15th total of 6,900,000 shares. Based on an average trading volume of 1,450,000 shares, the short-interest ratio is presently 5.4 days.
View Natera's Short Interest
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our NTRA earnings forecast
.

How can I listen to Natera's earnings call?

Natera will be holding an earnings conference call on Wednesday, February 28th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) issued its quarterly earnings data on Wednesday, November, 8th. The medical research company reported ($0.95) earnings per share for the quarter, topping analysts' consensus estimates of ($0.96) by $0.01. The medical research company earned $268.30 million during the quarter, compared to analysts' expectations of $259.27 million. Natera had a negative net margin of 50.50% and a negative trailing twelve-month return on equity of 72.98%. Natera's revenue was up 27.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.25) earnings per share.

What guidance has Natera issued on next quarter's earnings?

Natera updated its fourth quarter 2023 earnings guidance on Tuesday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $300.0 million-$300.0 million, compared to the consensus revenue estimate of $276.0 million.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

(NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%), Norges Bank (1.12%) and Avidity Partners Management LP (0.92%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 2/22/2024 by MarketBeat.com Staff